Scynexis announces FDA approval of Brexafemme as the first and only oral non-azole treatment for vaginal yeast infections
Scynexis Inc.,. announced that the FDA has approved Brexafemme(ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Brexafemme which represents… read more.
